Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT06419348
Overview
99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA, which is promising as an excellent imaging agent applicable to PSMA positive prostate cancer. This study will investigate the safety, biodistribution and potential usefulness of 99mTc-QULIC-5-P1 SPECT imaging for the diagnosis of lesions in PSMA positive prostate cancer.
Sponsor
First Affiliated Hospital of Chongqing Medical University
Phase
Early Phase 1
Contacts
Xiaoyang Zhang, PhD
zhangxy@mail.bnu.edu.cn
023-89011755
ClinicalTrials.gov
NCT06419348Help us improve your experience